With regard to immunotherapy of prostate cancer, several prostatic tissue-confined antigens have been described, such as prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), prostate acid phosphatase (PAP) and prostate secretory protein-94 (PSP94). Here, FOLH1 is linked to prostate carcinoma.